Literature DB >> 14685797

Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy.

M P Lichy1, P Bachert, M Henze, C M Lichy, J Debus, H P Schlemmer.   

Abstract

Since antineoplastic activity varies, sensitive methods for individual assessment of efficacy are needed. We demonstrate the clinical value of MR spectroscopy in monitoring chemotherapy in a patient with recurrent glioma after stereotactic radiotherapy. Diagnostic imaging before and after chemotherapy included contrast-enhanced MRI, single-voxel proton MR spectroscopy ((1)H MRS), (1)H MR spectroscopic imaging ((1)H SI), and fluorodeoxyglucose (FDG) positron-emission tomography (PET). A significant decrease in choline signal intensity was observed 2 months after chemotherapy indicating tumour chemosensitivity, in line with tumour shrinkage on MRI and decreased uptake of FDG. Assessment of early response by MRS may help to improve treatment protocols in other patients.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14685797     DOI： 10.1007/s00234-003-1116-8

Source DB:  PubMed          Journal:  Neuroradiology        ISSN： 0028-3940            Impact factor:   2.804


  9 in total

1.  Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors.

Authors:  S J Nelson
Journal:  Magn Reson Med       Date:  2001-08       Impact factor: 4.668

2.  Automated spectral analysis III: application to in vivo proton MR spectroscopy and spectroscopic imaging.

Authors:  B J Soher; K Young; V Govindaraju; A A Maudsley
Journal:  Magn Reson Med       Date:  1998-12       Impact factor: 4.668

3.  Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.

Authors: 
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

4.  Proton magnetic resonance spectroscopy of late delayed radiation-induced injury of the brain.

Authors:  Y L Chan; D K Yeung; S F Leung; G Cao
Journal:  J Magn Reson Imaging       Date:  1999-08       Impact factor: 4.813

5.  Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy.

Authors:  H P Schlemmer; P Bachert; K K Herfarth; I Zuna; J Debus; G van Kaick
Journal:  AJNR Am J Neuroradiol       Date:  2001-08       Impact factor: 3.825

Review 6.  PET in differentiation of recurrent brain tumor from radiation injury.

Authors:  D D Langleben; G M Segall
Journal:  J Nucl Med       Date:  2000-11       Impact factor: 10.057

7.  Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy.

Authors:  M C Preul; Z Caramanos; J G Villemure; G Shenouda; R LeBlanc; A Langleben; D L Arnold
Journal:  Neurosurgery       Date:  2000-02       Impact factor: 4.654

8.  Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy.

Authors:  M E Meyerand; J M Pipas; A Mamourian; T D Tosteson; J F Dunn
Journal:  AJNR Am J Neuroradiol       Date:  1999-01       Impact factor: 3.825

9.  Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy.

Authors:  M C Preul; Z Caramanos; D L Collins; J G Villemure; R Leblanc; A Olivier; R Pokrupa; D L Arnold
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440
  9 in total
  8 in total

1.  Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study.

Authors:  Fatma Al-Saeedi
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

Review 2.  Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.

Authors:  Alexander Lin; Brian D Ross; Kent Harris; Willis Wong
Journal:  NeuroRx       Date:  2005-04

Review 3.  Imaging of brain tumors: MR spectroscopy and metabolic imaging.

Authors:  Alena Horská; Peter B Barker
Journal:  Neuroimaging Clin N Am       Date:  2010-08       Impact factor: 2.264

4.  Rodent rhabdomyosarcoma: comparison between total choline concentration at H-MRS and [18F]-fluoromethylcholine uptake at PET using accurate methods for collecting data.

Authors:  Denis Rommel; Anne Bol; Jorge Abarca-Quinones; Frank Peeters; Annie Robert; Daniel Labar; Christine Galant; Vincent Gregoire; Thierry Duprez
Journal:  Mol Imaging Biol       Date:  2009-11-25       Impact factor: 3.488

5.  Monitoring of treatment response after chemoradiotherapy for head and neck cancer using in vivo 1H MR spectroscopy.

Authors:  Ann D King; David K W Yeung; Kwok-Hung Yu; Frankie K F Mo; Chen-Wen Hu; Kunwar S Bhatia; Gary M K Tse; Alexander C Vlantis; Jeffrey K T Wong; Anil T Ahuja
Journal:  Eur Radiol       Date:  2009-08-05       Impact factor: 5.315

Review 6.  The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Timothy Charles Ryken; Nafi Aygun; Johnathan Morris; Marin Schweizer; Rajeshwari Nair; Cassandra Spracklen; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-09       Impact factor: 4.130

7.  The Treatment of Malignant Gliomas.

Authors:  Mark R Gilbert; Monica Loghin
Journal:  Curr Treat Options Neurol       Date:  2005-07       Impact factor: 3.972

8.  Comments and controversies: magnetic resonance spectroscopy and gliomas.

Authors:  Guoguang Fan
Journal:  Cancer Imaging       Date:  2006-09-07       Impact factor: 3.909
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.